| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2976937 | Journal of Nuclear Cardiology | 2008 | 9 Pages |
Abstract
CTCA is associated with non-negligible risk of malignancy. Doses can be reduced by careful attention to scanning protocol.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Andrew J. MD, PhD, Javier MD, Santo MD, Margherita PhD, Marc MD, PhD, Milena MD, Sanjay MD,